Hua is a leading, clinical stage innovative drug development company in China focused on novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA enabling stage and started 2 Phase 3 trials in China for drug naive and metformin treated T2D patients. The company also has initiated product life-cycle management studies of this novel diabetes drug, and advanced knowledge in personalized diabetes care. Hua's strategy is to leverage the cost-efficient and high-quality drug development capabilities available in China, while working very closely with disease experts in China and rest of world to advance diabetes care solutions for global patients.
The trial is a pharmacokinetic and pharmacodynamic study of dorzagliatin in combination with empagliflozin to investigate the PK/PD of each drug alone or in combination.
Hua Medicine (the “Company”, Stock Code: 2552.HK) today announced its consolidated results for the year ended December 31, 2018 (the “Review Period”). As of December 31, 2018, the Company’s cash position was approximately RMB 1,443.3 million.
Copyright © 2019 Hua Medicine, All Rights Reserved沪ICP备14036654号